Skip to content

The expression of DKK1 in bone metastasis of prostate cancer and its influence on prognosis

The expression of DKK1 in bone metastasis of prostate cancer and its influence on prognosis

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050897
Enrollment
Unknown
Registered
2021-09-07
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Prostate cancer group:Nil
Control group:No

Sponsors

Guizhou Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
25 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged 25-90 years; 2. Prostate cancer has received chemotherapy, surgery, targeted therapy or no other tumors.

Exclusion criteria

Exclusion criteria: 1. Recently used drugs that may affect PSA (such as statins, thiazides and other diuretics, NSAIDS, androgens and their derivatives, 5-alpha reductase inhibitors); 2. Patients with recent prostatitis, urinary tract infection or recent history of prostate operation (i.e. rectal examination within 1 week, prostate biopsy, surgery or cystoscopy within 1 month); 3. A history of other metabolic bone diseases, such as Paget's disease of bone or primary hyperparathyroidism.

Design outcomes

Primary

MeasureTime frame
Secreted protein;

Countries

China

Contacts

Public ContactHe Hu

Guizhou Provincial People's Hospital

1012194806@qq.com+86 13138113536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026